Ensemble Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Ensemble Therapeutics's estimated annual revenue is currently $2.3M per year.
- Ensemble Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Ensemble Therapeutics has 15 Employees.
- Ensemble Therapeutics grew their employee count by 0% last year.
Ensemble Therapeutics's People
Name | Title | Email/Phone |
---|
Ensemble Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Ensemble Therapeutics?
Ensemble is the first company to successfully and reliably exploit synthetic macrocycle drugs, called Ensemblinsâ„¢. With their distinctive macrocyclic ring structure, Ensemblins have unique properties to address difficult-to-address drug targets that are known to play key roles in disease processes, yet are currently undruggable with conventional small molecule drugs. With their unique chemical and biological properties, Ensemblins are a new class of drugs in the emerging therapeutic space between small molecules and biologics. Ensemble's leadership capabilities in developing macrocycle drugs are based on the company's proprietary, DNA-programmed chemistry drug discovery platform. The company has a pipeline of proprietary and partnered Ensemblin drug candidates to treat a broad range of diseases, including inflammation, oncology and diabetes.
keywords:N/AN/A
Total Funding
15
Number of Employees
$2.3M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Ensemble Therapeutics News
... therapeutics, and vaccines), staffing needs, and school closures (3). ... Preliminary research suggested that COVID-19 ensemble forecasts were also more...
ENSEM Chief Scientific Officer Shengfang Jin said Kinetic Ensemble is capable of revealing new targets for drug development and can lead to the...
ENSEM is a pioneering drug discovery and development company that leverages its unique Kinetic EnsembleTM platform to develop innovative small...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.5M | 15 | -40% | N/A |
#2 | $2.3M | 15 | N/A | N/A |
#3 | $0.9M | 15 | N/A | N/A |
#4 | $1.3M | 15 | N/A | N/A |
#5 | $1M | 15 | 7% | N/A |